ORG Wealth Partners LLC Has $405,000 Stake in Illumina, Inc. (NASDAQ:ILMN)

ORG Wealth Partners LLC increased its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 68.1% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 3,030 shares of the life sciences company’s stock after acquiring an additional 1,227 shares during the quarter. ORG Wealth Partners LLC’s holdings in Illumina were worth $405,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Versant Capital Management Inc increased its holdings in shares of Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company’s stock valued at $32,000 after purchasing an additional 146 shares during the last quarter. TD Private Client Wealth LLC raised its holdings in Illumina by 58.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company’s stock valued at $50,000 after acquiring an additional 141 shares during the period. Massmutual Trust Co. FSB ADV lifted its position in Illumina by 65.1% during the third quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company’s stock worth $56,000 after acquiring an additional 168 shares during the last quarter. Private Trust Co. NA boosted its holdings in shares of Illumina by 81.2% during the third quarter. Private Trust Co. NA now owns 473 shares of the life sciences company’s stock worth $62,000 after acquiring an additional 212 shares during the period. Finally, Focused Wealth Management Inc acquired a new position in shares of Illumina in the third quarter valued at approximately $63,000. Institutional investors own 89.42% of the company’s stock.

Wall Street Analysts Forecast Growth

ILMN has been the subject of several recent research reports. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and reduced their price target for the company from $190.00 to $165.00 in a research note on Wednesday, December 11th. Stephens lifted their price objective on shares of Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Barclays increased their target price on shares of Illumina from $135.00 to $145.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. JPMorgan Chase & Co. lifted their price target on shares of Illumina from $125.00 to $140.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, TD Cowen raised their price objective on Illumina from $166.00 to $177.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Eight analysts have rated the stock with a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $165.95.

Illumina Price Performance

NASDAQ:ILMN traded down $4.22 on Friday, hitting $135.46. The company had a trading volume of 531,349 shares, compared to its average volume of 1,255,647. Illumina, Inc. has a 52 week low of $100.08 and a 52 week high of $156.66. The stock has a market capitalization of $21.48 billion, a price-to-earnings ratio of -13.60 and a beta of 1.11. The company has a current ratio of 2.43, a quick ratio of 1.85 and a debt-to-equity ratio of 0.94. The firm has a 50 day moving average of $141.37 and a two-hundred day moving average of $132.08.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, topping analysts’ consensus estimates of $0.88 by $0.26. The company had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. Illumina’s revenue was down 3.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.33 earnings per share. On average, research analysts anticipate that Illumina, Inc. will post 4.11 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.